Fortrea Holdings Inc. (FTRE)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Fortrea Holdings Inc. (FTRE) is a publicly traded company in the Healthcare sector. Latest price: $25.88. Market cap $2.46B. Trailing PE -27.83. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Valuation
| P/E (TTM) | -27.83× |
|---|---|
| P/S (TTM) | 0.92× |
| P/B | 4.65× |
| P/FCF (TTM) | 16.34× |
| EV / EBITDA | 42.00× |
| EV / Sales | 1.27× |
| Earnings Yield | -3.49% |
| Free Cash Flow Yield | 6.12% |
Fundamentals
| Enterprise Value | $3.41B |
|---|---|
| Revenue (TTM) | $2.68B |
| Net Income (TTM) | -$85.94M |
| Free Cash Flow (TTM) | $242.59M |
| Net Debt | $948.90M |
| Working Capital | -$40.10M |
| Gross Margin | 17.11% |
| Operating Margin | 0.41% |
| Net Margin | -3.18% |
| Return on Equity | -15.53% |
| Return on Invested Capital | 0.62% |
Peers
Recent News
- Fortrea to Participate in Jefferies Global Healthcare Conference
- Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development
- Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
- Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
- 3 Top Small-Cap Stocks With Market-Beating Momentum
Related
Browse more tickers: sitemap